Protalix BioTherapeutics will comment on the business results for the quarter ended March 31, 2020 on June 1, 2020.
The estimate of 1 analyst is $ 0,000 per share. In the prior year quarter, Protalix BioTherapeutics reported EPS of $ -0,500 per share.
1 analyst expects an increase of 25.00 percent on the revenue side compared to the revenue of USD 10.4 million generated in the previous year’s quarter. Accordingly, the expert at Protalix BioTherapeutics expects sales of $ 13.0 million for the past quarter.
In total, 2 analysts expect an average loss of $ -0.850 per share for the current fiscal year, compared to $ -1.230 per share in the previous year. 2 analysts average annual sales of USD 45.6 million. Last year there were $ 54.7 million on the books.
Editorial office finanzen.at
– .
